Order Article Reprints

Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, Morgenstern A, Seimbille Y, Koolen SLW, Brabander T, et al. Development of [²²⁵Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics. 2021; 13(5):715. https://doi.org/10.3390/pharmaceutics13050715

Hooijman, Eline L., Yozlem Chalashkan, Sui Wai Ling, Figen F. Kahyargil, Marcel Segbers, Frank Bruchertseifer, Alfred Morgenstern, Yann Seimbille, Stijn L. W. Koolen, Tessa Brabander, and et al. 2021. "Development of [²²⁵Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC" Pharmaceutics 13, no. 5: 715. https://doi.org/10.3390/pharmaceutics13050715

Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., & de Blois, E. (2021). Development of [²²⁵Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics, 13(5), 715. https://doi.org/10.3390/pharmaceutics13050715